Lexeo Therapeutics, Inc. (LXEO) News
Track canonical SquawkNews coverage tagged to LXEO, Lexeo Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
LXEO Reports Q2 2026 Financial Results
LXEO reports second quarter 2026 financial results and operational highlights
EARNINGS | Aug 12, 2026, 11:00 AM UTC
L
LXEO - Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhyt
LXEO - Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
REGULATION | Aug 05, 2026, 11:01 AM UTC
M
LXEO: JP Morgan Lowers Target
JP Morgan maintains Overweight on Lexeo Therapeutics, lowers price target to $9
EQUITY | Jun 25, 2026, 02:54 PM UTC